Wave Life Sciences .(WVE) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - Revenue for Q4 2025 was $17.2 million, down from $83.7 million in the prior year quarter, and full year revenue was $42.7 million compared to $108.3 million in 2024, primarily due to the termination of the Takeda collaboration [25][26] - Research and development expenses increased to $52.8 million in Q4 2025 from $44.6 million in Q4 2024, and for the full year, R&D expenses were $182.8 million compared to $159.7 million in 2024 [25][26] - The net loss for Q4 2025 was $53.2 million, compared to a net income of $29.3 million in the prior year quarter, and the full year net loss was $204.4 million compared to a net loss of $97 million in 2024 [27] Business Line Data and Key Metrics Changes - The company is focusing on two main programs: WVE-007 for obesity and WVE-006 for alpha-1 antitrypsin deficiency (AATD), with significant advancements in both areas [5][14] - WVE-007 showed promising interim data with a placebo-adjusted 4% reduction in total fat and a 9.2% reduction in visceral fat after three months at the lowest therapeutic dose [21] - WVE-006 demonstrated the ability to restore M-AAT protein levels to therapeutically meaningful levels, with over 11 micromolar protein and greater than 50% editing achieved [16] Market Data and Key Metrics Changes - The obesity treatment market is evolving, with a shift towards therapies that focus on body composition rather than just weight loss, highlighting the need for innovative mechanisms beyond current options like GLP-1s [7][13] - The company aims to address the unmet needs in the AATD market, where current treatment options are limited, and there is a significant patient population in need of effective therapies [14][15] Company Strategy and Development Direction - The company is strategically focused on accelerating the development of WVE-007 and advancing its RNA editing portfolio, with plans to initiate new clinical trials in 2026 [28] - There is a recognition of the need for novel obesity mechanisms and therapeutics, with WVE-007 positioned as a potential game-changer in the obesity landscape due to its unique dosing regimen and safety profile [13][28] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ongoing clinical trials and the potential for WVE-007 and WVE-006 to meet significant unmet medical needs, with expectations for regulatory feedback on accelerated approval pathways by mid-2026 [32][42] - The company is optimistic about the future, aiming to unlock the full potential of its RNA medicines pipeline to transform human health [28] Other Important Information - The company ended 2025 with $602.1 million in cash and cash equivalents, which is expected to fund operations into the third quarter of 2028 [27] - The collaboration with GSK is progressing, with potential milestone payments expected in 2026 and beyond [18] Q&A Session Summary Question: How closely does your regulatory strategy mirror a competitor's recent alignment with the FDA? - Management indicated that their regulatory strategy is aligned with existing therapies for AATD, focusing on a biomarker approach and anticipates positive discussions with the FDA [31][32] Question: Will there be data updates for the 400 mg multi and 600 mg single doses? - Management confirmed that data is on track and will be included in the next update, emphasizing the ongoing data collection from the study [36][37] Question: What are the expectations for confirmatory trial requirements for AATD? - Management stated that they aim to establish an accelerated approval pathway for AATD patients and will align with the agency on the necessary requirements [42][43] Question: What outcomes data are planned to minimize potential payer pushbacks for obesity treatment? - Management highlighted the importance of demonstrating significant fat loss and lean mass preservation to support regulatory pathways and address payer concerns [48][50] Question: What treatment delta is expected for MRI-PDFF in the upcoming obesity trial? - Management noted that there is a substantial opportunity for liver fat reduction and emphasized the importance of monitoring these outcomes in the context of MASH [65][66]